Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39,246 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC.
Chu T, Zhong R, Zhong H, Zhang B, Zhang W, Shi C, Qian J, Zhang Y, Chang Q, Zhang X, Dong Y, Teng J, Gao Z, Qiang H, Nie W, Zhao Y, Han Y, Chen Y, Han B. Chu T, et al. Among authors: zhang b, zhang w, zhang x, zhang y. J Thorac Oncol. 2021 Apr;16(4):643-652. doi: 10.1016/j.jtho.2020.11.026. Epub 2021 Jan 29. J Thorac Oncol. 2021. PMID: 33524601 Free article. Clinical Trial.
First-line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non-squamous non-small cell lung cancer with wild-type driver genes: A real-world study in China.
Chang Q, Zhang Y, Xu J, Zhong R, Qiang H, Zhang B, Han B, Qian J, Chu T. Chang Q, et al. Among authors: zhang b, zhang y. Thorac Cancer. 2019 May;10(5):1043-1050. doi: 10.1111/1759-7714.13025. Epub 2019 Mar 22. Thorac Cancer. 2019. PMID: 30900826 Free PMC article.
Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies.
Qian J, Nie W, Lu J, Zhang L, Zhang Y, Zhang B, Wang S, Hu M, Xu J, Lou Y, Dong Y, Niu Y, Yan B, Zhong R, Zhang W, Chu T, Zhong H, Han B. Qian J, et al. Among authors: zhang l, zhang b, zhang w, zhang y. Int J Cancer. 2020 Jun 1;146(11):3124-3133. doi: 10.1002/ijc.32717. Epub 2019 Nov 1. Int J Cancer. 2020. PMID: 31583695 Free article.
Going Beyond Results of the PEMBRO-RT Trial.
Zhang B, Han B. Zhang B, et al. JAMA Oncol. 2020 Jan 1;6(1):161-162. doi: 10.1001/jamaoncol.2019.5031. JAMA Oncol. 2020. PMID: 31750867 No abstract available.
Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study).
Zhang B, Shi C, Gao Z, Zhong H, Xiong L, Gu A, Wang W, Chu T, Zhang W, Wang H, Zhang X, Zhong R, Han B. Zhang B, et al. Among authors: zhang w, zhang x. BMC Cancer. 2022 Mar 19;22(1):294. doi: 10.1186/s12885-022-09409-3. BMC Cancer. 2022. PMID: 35305596 Free PMC article.
39,246 results
You have reached the last available page of results. Please see the User Guide for more information.